The concurrence of rheumatoid arthritis and limited systemic sclerosis: Clinical and serologic characteristics of an overlap syndrome

Zimmermann, Christof; Steiner, Günter; Skriner, Karl; Hassfeld, W.; Petera, P; Smolen, Josef S.

doi:10.1002/1529-0131(199811)41:11<1938::aid-art7>3.3.co;2-o

Cited by 1 publication

(2 citation statements)

References 16 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, such a correlation was not seen in hyperlipidemic patients with an increased risk for atherosclerosis and arterial stiffness. To the best of our knowledge, this is the first report of a significant association of anti-hnRNP B1 autoantibodies with hypertension in SARD and could support the existence of an overlap between RA and SSc [ 20 ].…”

Section: Discussionmentioning

confidence: 77%

“…Significantly higher anti-hnRNP B1 autoantibody prevalences and levels were found in patients with RA and SSc. Interestingly, an overlap syndrome of RA and limited SSc has been described, which was characterized by an incomplete CREST syndrome and cross-reactivity of anticentromere with anti-hnRNP B1 autoantibodies [ 20 , 21 ]. Recently, an association of anti-hnRNP autoantibodies with erosive arthritis has been described in patients with SSc [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-hnRNP B1 (RA33) Autoantibodies Are Associated with the Clinical Phenotype in Russian Patients with Rheumatoid Arthritis and Systemic Sclerosis

Maslyansky

Lazareva

Olinek³

et al. 2014

Journal of Immunology Research

View full text Add to dashboard Cite

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are potent autoantigenic targets in systemic autoimmune rheumatic diseases (SARD). Loss of tolerance to the RA33 complex consisting of hnRNP A2 and its alternatively spliced variants B1 and B2 has been the interest of rheumatologists. A novel ELISA for the detection of anti-hnRNP B1 autoantibodies has been developed to investigate the prevalence thereof in 397 patients with SARD, including patients with rheumatoid arthritis (RA), spondyloarthropathy (SPA), juvenile chronic arthritis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren's syndrome (SS), in comparison to 174 controls. Anti-hnRNP B1 autoantibodies were significantly more prevalent in patients with SARD than controls (47/397, 11.8% versus 2/174, 1.1%; P < 0.001). In particular, anti-hnRNP B1 were found more frequently in the disease cohorts than in the controls and were present in 24/165 (14.5%) patients with RA, 6/58 (10.3%) SPA, 11/65 (16.9%) SSc, and 4/50 (8.0%) SLE. In RA patients, anti-hnRNP B1 autoantibodies correlated significantly with C-reactive protein levels and erythrocyte sedimentation rate, while in patients with SSc it was associated with features of arterial wall stiffness and presence of hypertension. Anti-hnRNP B1 autoantibodies occur in SARD and seem to be correlated with distinct clinical characteristics in patients with RA and SSc.

show abstract

Section: Discussionmentioning

confidence: 77%